The patient, who has ALS, is the first to sign up for Synchron’s FDA-approved clinical trial at Mount Sinai targeting patients with paralysis. The patient has the company’s stentrode implanted into their motor cortex where it will translate brain activity into digital information, with the end goal of allowing the patient to control digital devices without their physical movement.
The surgery makes the patient the first in the U.S. to receive the treatment. Four patients in Australia have already been fitted with Synchron’s device and were able to message on WhatsApp and shop online hands-free.
“This surgery was special because of its implications and huge potential,” said Shahram Majidi, MD, who inserted the device.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
